Media Coverage

Monday, August 29, 2016

CardioCell offers bright spot in stem cell development


CardioCell reported positive Phase II data for its intravenous stem cell therapy for the treatment of chronic heart failure at the European Society of Cardiology meeting in Rome on Sunday.

The study represented the first positive trial of IV ischemia-tolerant mesenchymal stem cells (itMSCs) in patients with chronic heart failure, after several other companies have failed in the space. READ FULL ARTICLE

Sunday, August 28, 2016

Stem cells to repair the heart. The enterprise is more difficult than expected

HealthDesk Italy

The idea is one that could revolutionize the treatment of heart disease: use stem cells to repair the heart in cases where it has been damaged by a heart attack or when it lost its structural and functional characteristics, as in heart failure. 

However, this horse on which cardiology has focused for some time has so far produced mixed results; best in the case of ischemic heart disease worse in those non-ischemic. READ FULL ARTICLE

Stem-Cell Therapy Trials Miss Mark but Keep Hope Alive


Two stem-cell trials, two negative primary end points, but signals of benefit in each may keep hope alive in patients with heart failure (HF), despite a decade of disappointment in the field.

A phase 2a trial found that IV administration of allogeneic ischemia-tolerant mesenchymal stem cells (itMSC) derived from a single healthy donor did not effect left ventricular (LV) function in 22 patients with nonischemic HF and an ejection fraction <40% (P=0.99). READ FULL ARTICLE

Studies Explore Safety and Efficacy of Stem Cell Therapies


Safety and efficacy of stem cell therapies were explored in two separate trials presented on Aug. 28 during ESC Congress 2016 in Rome. … Meanwhile, a single dose of mesenchymal stem cells delivered intravenously to patients with chronic non-ischemic cardiomyopathy was not associated with significant cardiac structural or functional improvements, but did result in several clinically relevant benefits, according to results from a phase II-a randomized trial. READ FULL ARTICLE

Wednesday, June 15, 2016

European Society of Cardiology Selects CardioCell’s Heart Failure (HF) Study Results For ESC Congress 2016 Late-Breaking Science Session

BioSpace logo

CardioCell LLC, a global biotechnology company that uses allogeneic stem cells for cardiovascular indications, announces that the European Society of Cardiology (ESC) has accepted data from CardioCell’s Phase IIa heart failure (HF) study for an ESC Congress 2016 “Hot Line” Late-Breaking Science Session, a track that features innovative approaches for novel clinical trials that are being presented for the first time. READ FULL ARTICLE

Older Entries » « Newer Entries